• New Launches

WuXi STA Launches its First Parenteral Formulation Manufacturing Line

Shanghai, January 21, 2022: WuXi STA, a subsidiary of WuXi AppTec, today announced its first parenteral formulation manufacturing line at the Wuxi…

• Latest

WuXi STA Forms Strategic Partnership with Coherent Biopharma

Shanghai, December 03, 2021: WuXi STA – a subsidiary of WuXi AppTec– and Coherent Biopharma, announced the signing of a strategic…

• US FDA Approval

WuXi STA Shanghai & Changzhou Facilities Pass U.S. FDA Inspections

Shanghai, July 23, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – announces that its Analytical Service Unit…

• News

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

Shanghai, May 22, 2019: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical,…

WuXi AppTec Partner Hutchison MediPharma Receives Approval of Fruquintinib Capsules in China

Shanghai, November 15, 2018: WuXi AppTec congratulates its partner Hutchison MediPharma (HMP) on receiving approval of Fruquintinib capsules (Elunate®) for metastatic…

• Archives

WuXi STA’s Jinshan Site Passes Fourth U.S. FDA Inspection

Shanghai, July 29, 2018: STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, announces that its Active Pharmaceutical Ingredient (API)…

WuXi STA and Antengene Sign Development and Manufacturing Agreement

Shanghai, July 24, 2018: STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Antengene Corporation, a…

WuXi STA first CDMO to support the approval of an innovative drug in China through the “MAH” pilot

WuXi STA enables Ascletis to receive NDA Approval from China FDA for Ganovo® Shanghai, June 15, 2018: STA Pharmaceutical Co., Ltd. (WuXi…

• Archives

WuXi STA Changzhou Site Passes First U.S. FDA Inspection

The integrated R&D and manufacturing facility is expecting more products to go into commercial production post approval Shanghai, May 11,…

Phoenix Molecular Designs Announces Manufacturing Collaboration with WuXi STA to advance PMD-026 toward IND

MD-026 is the first RSK inhibitor to demonstrate potential disease-modifying properties in triple-negative breast cancer (TNBC)  Vancover, April 19, 2018: Phoenix…